AU2022374887A1 - Combination therapy of radionuclide complex - Google Patents

Combination therapy of radionuclide complex Download PDF

Info

Publication number
AU2022374887A1
AU2022374887A1 AU2022374887A AU2022374887A AU2022374887A1 AU 2022374887 A1 AU2022374887 A1 AU 2022374887A1 AU 2022374887 A AU2022374887 A AU 2022374887A AU 2022374887 A AU2022374887 A AU 2022374887A AU 2022374887 A1 AU2022374887 A1 AU 2022374887A1
Authority
AU
Australia
Prior art keywords
dota
weeks
subject
radiopharmaceutical compound
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022374887A
Other languages
English (en)
Inventor
Paola Daniela AIMONE
Daniela Chicco
Maurizio F. MARIANI
Evren ZOR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Advanced Accelerator Applications SA
Original Assignee
Novartis AG
Advanced Accelerator Applications SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Advanced Accelerator Applications SA filed Critical Novartis AG
Publication of AU2022374887A1 publication Critical patent/AU2022374887A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2022374887A 2021-10-27 2022-10-27 Combination therapy of radionuclide complex Pending AU2022374887A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272447P 2021-10-27 2021-10-27
US63/272,447 2021-10-27
PCT/IB2022/060331 WO2023073603A1 (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Publications (1)

Publication Number Publication Date
AU2022374887A1 true AU2022374887A1 (en) 2024-04-11

Family

ID=84365353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022374887A Pending AU2022374887A1 (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Country Status (11)

Country Link
US (1) US20250387523A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422701A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539952A (cg-RX-API-DMAC7.html)
KR (1) KR20240093832A (cg-RX-API-DMAC7.html)
CN (1) CN118159304A (cg-RX-API-DMAC7.html)
AU (1) AU2022374887A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234495A1 (cg-RX-API-DMAC7.html)
IL (1) IL312106A (cg-RX-API-DMAC7.html)
MX (1) MX2024004961A (cg-RX-API-DMAC7.html)
TW (1) TW202332473A (cg-RX-API-DMAC7.html)
WO (1) WO2023073603A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129912B1 (en) * 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods

Also Published As

Publication number Publication date
IL312106A (en) 2024-06-01
CA3234495A1 (en) 2023-05-04
JP2024539952A (ja) 2024-10-31
CN118159304A (zh) 2024-06-07
MX2024004961A (es) 2024-05-08
US20250387523A1 (en) 2025-12-25
KR20240093832A (ko) 2024-06-24
WO2023073603A1 (en) 2023-05-04
EP4422701A1 (en) 2024-09-04
TW202332473A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
Dilworth et al. The chemistry of PET imaging with zirconium-89
JP7839135B2 (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用
Maini et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases
JP2024541595A (ja) 放射線医薬的治療方法及び使用
WO2024176147A1 (en) Methods for treating breast cancer
KR20250140611A (ko) 교모세포종의 치료 방법
Bushnell et al. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher™) in patients with diffuse somatostatin receptor positive liver metastases
EP4422701A1 (en) Combination therapy of radionuclide complex
Chakraborty et al. Evaluation of; 177Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
US7709613B2 (en) Rhenium-188 and rhenium-186 for treatment of tumors expressing a Na+/I− symporter
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
KR20260014588A (ko) 전립선암의 진단 및/또는 치료 방법
WO2025000035A1 (en) Methods for the diagnosis and/or treatment of neuroendocrine cancers
KR20250109190A (ko) 암의 식별 및/또는 치료
Choi Radionuclide-Dependent Immune Modulation in GD2-and Bone-Targeted Radiopharmaceutical Therapy Combined With Immune Checkpoint Inhibitors
US20230064292A1 (en) Methods of treating psma-positive cancer using radionuclide therapy
WO2025126151A1 (en) Methods for treating breast cancer
WO2025145255A1 (en) Lat-1 targeting amino acid derivatives and uses thereof
Saiful Alam Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody
US20080247947A1 (en) High dose 111In-pentetreotide therapy of neuroendocrine tumors
Mueller-Brand et al. Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1, 4, 7, 10-Tetraazacyclododecane-1-Glutaric Acid-4, 7, 10-Triacetic Acid-Substance P